Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Polaryx Therapeutics, Inc.
PLYX
Other
Executive Educational Background Disclosure
Kol Endorsement
Executive Transition Gratitude Statement
Enrollment Ahead Of Schedule
Interim Data Positive
Core
Lead Asset Progress
Indication Expansion
Other
Financing Activities Cash Flow Disclosure
Net Loss Reported
Personnel Cost Decrease Disclosure
Emerging Growth Company Status Disclosed
Capital Raising Uncertainty Disclosed
Valuation Allowance Deferred Tax Disclosure
Operating Lease Rent Expense Disclosed
Shares Outstanding Disclosure
Institutional Investment
Protocol Amended
Significant Accounting Estimates Disclosure
Administrative Efficiency
Acquisition And Management Fees Disclosed
Burn Rate Controlled
Core
Management Exodus
Other
Successor Agent Appointment Provision
Other
Record Date Disclosure
Annual Meeting Notice Disclosure
Other
Corporate Organization And Standing Representation
Amendment Modification Waiver Clause
Nyse Listing Disclosure
Non Assignment Clause
Closing Logistics Specified
Gene Therapy Aav
Closing Deliverables Specified
Institutional Investment
Survival Of Representations Warranties Clause
Safety Differentiated
Ipo Or Capital Raising Completion
Core
Combination Therapy Mentioned
Lead Asset Progress
Indication Expansion
Biotech v3
Ai Drug Discovery Investment
Other
Net Loss Reported
Financing Activities Cash Flow Disclosure
Equity Award Plan Types Enumerated
Emerging Growth Company Status Disclosed
Deferred Tax Asset Valuation Disclosure
Capital Raising Uncertainty Disclosed
Segment Aggregation Disclosure
Equity Plan Share Reserve Disclosure
Nyse Listing Disclosure
Share Repurchase Activity Disclosed
Valuation Allowance Deferred Tax Disclosure
Liquidity Position Snapshot Disclosed
Operating Lease Rent Expense Disclosed
Shares Outstanding Disclosure
Core
Indication Expansion